DRG Epidemiology's coverage neuroblastoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of neuroblastoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's neuroblastoma forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with neuroblastoma per year?
Of all people diagnosed with neuroblastoma, how many in each country are first line drug-treatable?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuroblastoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts 5 neuroblastoma patient populations, as follows:
Diagnosed Incidence of Neuroblastoma per 100,000 People Aged 0-19 years in 2019 and 2029
Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of neuroblastoma over the Next Ten Years
Analysis of the Diagnosed Incident Case Neuroblastoma in 2019 by Stage Distribution
Number of Additional Diagnosed incident cases of Neuroblastoma incurred over 2019-2029 in the Countries Under Study
Epidemiology Data
Methods
Diagnosed Incident Cases
Stage Distribution of Neuroblastoma
Diagnosed Prevalence
Recurrent Incident Cases of Neuroblastoma
Drug-Treatable Populations
Reference Materials
Literature Review
Studies Included in the Analysis of Neuroblastoma
Studies Excluded from the Analysis of neuroblastoma
Risk/Protective Factors
Risk Factors for Neuroblastoma
Bibliography
Nishant Kumar, M.P.H.
Nishant Kumar, M.P.H., is a senior director on the Epidemiology team at Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Previously, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.
